These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 34585947

  • 1. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F, Gritsenko V, Lu H, Zhen C, Gao L, Berman J, Jiang YY.
    Microbiol Spectr; 2021 Oct 31; 9(2):e0072321. PubMed ID: 34585947
    [Abstract] [Full Text] [Related]

  • 2. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F, Hare Jensen R, Meis JF, Arendrup MC.
    Mycoses; 2016 Sep 31; 59(9):576-84. PubMed ID: 27061834
    [Abstract] [Full Text] [Related]

  • 3. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M, Zhang J, Messer S, Tumberland M, Mbidde E, Jessup C, Ghannoum M.
    Diagn Microbiol Infect Dis; 1998 Nov 31; 32(3):191-9. PubMed ID: 9884835
    [Abstract] [Full Text] [Related]

  • 4. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH, Huang PY, Cheng CW, Shie SS, Lin ZF, Yang LY, Lee CH, Wu TS.
    Med Mycol; 2021 Nov 03; 59(11):1114-1121. PubMed ID: 34374784
    [Abstract] [Full Text] [Related]

  • 5. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.
    J Mycol Med; 2012 Sep 03; 22(3):243-8. PubMed ID: 23518082
    [Abstract] [Full Text] [Related]

  • 6. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM, Almeida-Paes R, Brito-Santos F, Nascimento CR, Fialho MM, Trilles L, Morales BP, da Silva SA, Santos W, Santos LO, Fortes ST, Cardarelli-Leite P, Lázera MDS.
    Med Mycol; 2019 Oct 01; 57(7):864-873. PubMed ID: 30657975
    [Abstract] [Full Text] [Related]

  • 7. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R, Fuchs V, Graf B, Hamprecht A, Hogardt M, Sedlacek L, Schwarz R, Idelevich EA, Becker SL, Held J, Küpper-Tetzel CP, McCormick-Smith I, Heckmann D, Gerkrath J, Han CO, Wilmes D, Rickerts V.
    Int J Med Microbiol; 2019 Sep 01; 309(6):151336. PubMed ID: 31444102
    [Abstract] [Full Text] [Related]

  • 8. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the Cryptococcus neoformans Complex in Jiangxi Province, South Central China.
    Yang C, Bian Z, Blechert O, Deng F, Chen H, Li Y, Yang Y, Chen M, Zhan P.
    Front Cell Infect Microbiol; 2021 Sep 01; 11():723251. PubMed ID: 34790585
    [Abstract] [Full Text] [Related]

  • 9. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul 01; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P, Dromer F, Lortholary O, Dannaoui E.
    Antimicrob Agents Chemother; 2006 Jan 01; 50(1):113-20. PubMed ID: 16377675
    [Abstract] [Full Text] [Related]

  • 11. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN, Huang CR, Lei CB, Lee PY, Chien CC, Chang HW, Chang CS, Lu CH.
    Jpn J Infect Dis; 2004 Jun 01; 57(3):113-5. PubMed ID: 15218221
    [Abstract] [Full Text] [Related]

  • 12. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
    Larsen RA, Bauer M, Thomas AM, Graybill JR.
    Antimicrob Agents Chemother; 2004 Mar 01; 48(3):985-91. PubMed ID: 14982793
    [Abstract] [Full Text] [Related]

  • 13. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, Foongladda S.
    J Med Assoc Thai; 2006 Jun 01; 89(6):795-802. PubMed ID: 16850679
    [Abstract] [Full Text] [Related]

  • 14. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
    Vu K, Gelli A.
    Med Mycol; 2010 Mar 01; 48(2):255-62. PubMed ID: 19572230
    [Abstract] [Full Text] [Related]

  • 15. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB, Sujatha S, Parija SC.
    Indian J Pathol Microbiol; 2006 Apr 01; 49(2):307-8. PubMed ID: 16933750
    [Abstract] [Full Text] [Related]

  • 16. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
    Warnock DW, Johnson EM, Rogers TR.
    J Antimicrob Chemother; 1998 Sep 01; 42(3):321-31. PubMed ID: 9786472
    [Abstract] [Full Text] [Related]

  • 17. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
    Dannaoui E, Abdul M, Arpin M, Michel-Nguyen A, Piens MA, Favel A, Lortholary O, Dromer F, French Cryptococcosis Study Group.
    Antimicrob Agents Chemother; 2006 Jul 01; 50(7):2464-70. PubMed ID: 16801427
    [Abstract] [Full Text] [Related]

  • 18. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
    Moreira IMB, Cortez ACA, de Souza ÉS, Pinheiro SB, de Souza Oliveira JG, Sadahiro A, Cruz KS, Matsuura ABJ, Melhem MSC, Frickmann H, de Souza JVB.
    Med Mycol; 2022 Mar 03; 60(3):. PubMed ID: 35084497
    [Abstract] [Full Text] [Related]

  • 19. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E, Vitali LH, Kress MRVZ, Martinez R.
    Rev Inst Med Trop Sao Paulo; 2017 Mar 03; 59():e49. PubMed ID: 28793019
    [Abstract] [Full Text] [Related]

  • 20. Cryptococcus neoformans, Unlike Candida albicans, Forms Aneuploid Clones Directly from Uninucleated Cells under Fluconazole Stress.
    Chang YC, Khanal Lamichhane A, Kwon-Chung KJ.
    mBio; 2018 Dec 04; 9(6):. PubMed ID: 30514783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.